NorthWest Biotherapeutics Inc (NWBO)

[exwannabe]

Hence the change to overall survival — The GOLD STANDARD ..

They ran a trial.

The had an efficacy IA that showed the trial was futile. So they decided to wait on the secondary endpoint of OS (233 vs 99).

When that failed, they waited for a tail to show an OS advantage.

When that failed they used a glorified cross trial comparison (due to lack of patient level data).

Good luck with that.

Even LL says she hopes they can find some way such as RTT to get the drug to patients while waiting for a proper study to establish efficacy.